{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:42:08Z","timestamp":1793234528228,"version":"4.5.0"},"reference-count":43,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Buddhist Tzu Chi Medical Foundation grants","award":["TCMF-SP-108-01"],"award-info":[{"award-number":["TCMF-SP-108-01"]}]},{"name":"Buddhist Tzu Chi Medical Foundation grants","award":["TCMF-MP-110-03-01"],"award-info":[{"award-number":["TCMF-MP-110-03-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Purpose: A significant proportion of men without bladder outlet obstruction (BOO) have been reported to have overactive bladders (OAB). This article aimed to review the specific group of reports on the use of botulinum toxin type A (BTX-A) injections into the bladder wall. Materials and methods: Original articles reporting men with small prostates without BOO were identified through a literature search using the PubMed and EMBASE databases. Finally, we included 18 articles that reviewed the efficacy and adverse effects of BTX-A injections in men. Results: Of the 18 articles screened, 13 demonstrated the therapeutic efficacy and adverse effects of BTX-A injections in men. Three studies compared BTX-A injection response between patients without prior prostate surgery and those undergoing prior prostate surgery, including transurethral resection of the prostate and radical prostatectomy (RP). Patients with prior RP experienced better efficacy and had a low risk of side effects. Two studies focused on patients who had undergone prior surgery for stress urinary incontinence, including male sling and artificial urethral sphincter surgery. The BTX-A injection was a safe and effective procedure for this specific group. OAB in men was found to have a different pathophysiology mechanism from that in female patients, which may decrease the efficacy of BTX-A injection in men. However, patients with small prostates and low prostate-specific antigen levels demonstrated better efficacy and tolerability after BTX-A injection. Conclusions: Although intravesical injection of BTX-A was a good option for controlling refractory OAB in men, the evidence-based guidelines are still limited. Further research is necessary to better understand the role of BTX-A injections on various aspects and histories. Therefore, treating patients using strategies tailored to their individual conditions is important.<\/jats:p>","DOI":"10.3390\/toxins15030221","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T02:40:11Z","timestamp":1678934411000},"page":"221","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Intravesical Injection of Botulinum Toxin Type A in Men without Bladder Outlet Obstruction and Post-Deobstructive Prostate Surgery"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2405-4874","authenticated-orcid":false,"given":"Hsiang-Ying","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung 80756, Taiwan"},{"name":"Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80756, Taiwan"},{"name":"Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80756, Taiwan"},{"name":"Center for Cancer Research, Kaohsiung Medical University, Kaohsiung 80756, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7165-4771","authenticated-orcid":false,"given":"Hann-Chorng","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, Tzu Chi University, Hualien 970473, Taiwan"},{"name":"Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 970473, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Verhovsky, G., Baberashvili, I., Rappaport, Y.H., Zilberman, D.E., Neheman, A., Gal, J., Zisman, A., and Stav, K. (2022). Bladder Oversensitivity Is Associated with Bladder Outlet Obstruction in Men. J. Pers. Med., 12.","DOI":"10.3390\/jpm12101675"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1002\/nau.24076","article-title":"Do functional changes occur in the bladder due to bladder outlet obstruction?\u2014ICI-RS 2018","volume":"38","author":"Bosch","year":"2019","journal-title":"Neurourol. Urodyn."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: Impact of overactive bladder","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/nau.22295","article-title":"The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial\/ethnic group and age: Results from OAB-POLL","volume":"32","author":"Coyne","year":"2012","journal-title":"Neurourol. Urodyn."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC Study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4103\/ua.ua_9_21","article-title":"Urodynamic profile of lower urinary tract symptoms in young men: A testimony of the truth?","volume":"14","author":"Manohar","year":"2022","journal-title":"Urol. Ann."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1517\/14712598.2014.897322","article-title":"Intradetrusor onabotulinumtoxinA for overactive bladder","volume":"14","author":"Jambusaria","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/nau.23196","article-title":"Long-term compliance and results of intravesical botulinum toxin A injections in male patients","volume":"36","author":"Marcelissen","year":"2017","journal-title":"Neurourol. Urodyn."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/nau.24879","article-title":"Botulinum toxin for treating overactive bladder in men: A systematic review","volume":"41","author":"Truzzi","year":"2022","journal-title":"Neurourol. Urodyn."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wang, C.C., Chou, E.C., Chuang, Y.C., Lin, C.C., Hsu, Y.C., Liao, C.H., and Kuo, H.-C. (2021). Effectiveness and Safety of Intradetrusor OnabotulinumtoxinA Injection for Neurogenic Detrusor Overactivity and Overactive Bladder Patients in Taiwan-A Phase IV Prospective, Interventional, Multiple-Center Study (Restore Study). Toxins, 13.","DOI":"10.3390\/toxins13120911"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.toxicon.2021.07.005","article-title":"Correction of overactive bladder with botulinum toxin type A (BTX-A)","volume":"200","author":"Grishin","year":"2021","journal-title":"Toxicon"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.eururo.2008.06.032","article-title":"Tolterodine Extended Release with or Without Tamsulosin in Men with Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms: Effects of Prostate Size","volume":"55","author":"Roehrborn","year":"2009","journal-title":"Eur. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0090-4295(98)00655-4","article-title":"Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia","volume":"53","author":"Roehrborn","year":"1999","journal-title":"Urology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.urology.2008.06.067","article-title":"Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB","volume":"72","author":"Roehrborn","year":"2008","journal-title":"Urology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1007\/s11255-021-02962-z","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with overactive bladder: Subgroup analyses by sex and by serum prostate-specific antigen levels in men from a randomized controlled trial","volume":"53","author":"Yokoyama","year":"2021","journal-title":"Int. Urol. Nephrol."},{"key":"ref_16","unstructured":"Gravas, S., Cornu, J.N., Gacci, M., Gratzke, C., Herrmann TR, W., Mamoulakis, C., Rieken, M., Speakman, M.J., and Tikkinen, K.A.O. (2019). Management of Nonneurogenic Male Lower Urinary Tract Symptoms (LUTS), Including Benign Prostatic Obstruction (BPO), European Association of Urology."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S880","DOI":"10.4103\/jpbs.jpbs_893_21","article-title":"Exploration of Serum Prostatic Specific Antigen Level in Enlarged Prostate with its Histopathological Correlation","volume":"14","author":"Sharma","year":"2022","journal-title":"J. Pharm. Bioallied Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.urology.2019.08.054","article-title":"Predictors of Poor Response and Adverse Events Following Botulinum Toxin-A for Refractory Idiopathic Overactive Bladder","volume":"135","author":"Abrar","year":"2020","journal-title":"Urology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/JU.0000000000000525","article-title":"Treatment Response and Complications after Intradetrusor OnabotulinumtoxinA Injection in Male Patients with Idiopathic Overactive Bladder Syndrome","volume":"203","author":"Smet","year":"2020","journal-title":"J. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00404-010-1407-3","article-title":"Detrusor overactivity: An overview","volume":"282","author":"Ashok","year":"2010","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11255-011-9979-9","article-title":"Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity","volume":"44","author":"Kanagarajah","year":"2011","journal-title":"Int. Urol. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.urology.2018.09.016","article-title":"Onabotulinum toxin a Injections in Men With Refractory Idiopathic Detrusor Overactivity","volume":"123","author":"Syed","year":"2019","journal-title":"Urology"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Hsiao, S.-M., Lin, H.-H., and Kuo, H.-C. (2016). Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0147137"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"srep43753","DOI":"10.1038\/srep43753","article-title":"Urodynamic prognostic factors for large post-void residual urine volume after intravesical injection of onabotulinumtoxinA for overactive bladder","volume":"7","author":"Hsiao","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/nau.22892","article-title":"Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center","volume":"36","author":"Jiang","year":"2015","journal-title":"Neurourol. Urodyn."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.eururo.2010.09.007","article-title":"Adverse Events of Intravesical Botulinum Toxin a Injections for Idiopathic Detrusor Overactivity: Risk Factors and Influence on Treatment Outcome","volume":"58","author":"Kuo","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.juro.2012.11.089","article-title":"Increased Risk of Large Post-Void Residual Urine and Decreased Long-Term Success Rate After Intravesical OnabotulinumtoxinA Injection for Refractory Idiopathic Detrusor Overactivity","volume":"189","author":"Liao","year":"2013","journal-title":"J. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/nau.22642","article-title":"Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome","volume":"34","author":"Osborn","year":"2014","journal-title":"Neurourol. Urodyn."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/nau.21150","article-title":"Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: Lack of anticholinergic efficacy versus intolerability","volume":"30","author":"Makovey","year":"2011","journal-title":"Neurourol. Urodyn."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.juro.2006.10.047","article-title":"Botulinum Toxin Type A Injections Into the Trigone to Treat Idiopathic Overactive Bladder do Not Induce Vesicoureteral Reflux","volume":"177","author":"Karsenty","year":"2007","journal-title":"J. Urol."},{"key":"ref_31","first-page":"22","article-title":"Trigonal-sparing versus trigonal-involved Botox injection for treatment of idiopathic overactive bladder: A randomized clinical trial","volume":"13","author":"Elbaset","year":"2020","journal-title":"Low Urin. Tract. Symptoms"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.juro.2007.05.136","article-title":"Comparison of Effectiveness of Detrusor, Suburothelial and Bladder Base Injections of Botulinum Toxin A for Idiopathic Detrusor Overactivity","volume":"178","author":"Kuo","year":"2007","journal-title":"J. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/01.ju.0000169481.42259.54","article-title":"Decreased sensory receptors p2x 3 and trpv1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity","volume":"174","author":"Apostolidis","year":"2005","journal-title":"J. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1590\/S1677-5538.IBJU.2014.0221","article-title":"Efficacy of botulinum toxin type A 100 units versus 200 units for treatment of refractory idiopathic overactive bladder","volume":"41","author":"Abdelwahab","year":"2015","journal-title":"Int. Braz. J. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/j.1464-410X.2007.07186.x","article-title":"Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity","volume":"100","author":"Jeffery","year":"2007","journal-title":"BJU Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/nau.22780","article-title":"Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study","volume":"35","author":"Liao","year":"2016","journal-title":"Neurourol. Urodyn."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2011.12.011","article-title":"Repeated Botulinum Toxin Type A Injections for Refractory Overactive Bladder: Medium-Term Outcomes, Safety Profile, and Discontinuation Rates","volume":"61","author":"Dowson","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.urology.2009.05.097","article-title":"Repeated Injections of Botulinum Toxin-A for Idiopathic Detrusor Overactivity","volume":"75","author":"Sahai","year":"2010","journal-title":"Urology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1464-410X.2006.06735.x","article-title":"Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder","volume":"99","author":"Mitterberger","year":"2007","journal-title":"BJU Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/bju.13110","article-title":"Botulinum toxin (OnabotulinumtoxinA) in the male non-neurogenic overactive bladder: Clinical and quality of life outcomes","volume":"116","author":"Habashy","year":"2015","journal-title":"BJU Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.euf.2020.08.015","article-title":"Long-term Follow-up of Intravesical Onabotulinum Toxin-A Injections in Male Patients with Idiopathic Overactive Bladder: Comparing Surgery-na\u00efve Patients and Patients After Prostate Surgery","volume":"7","author":"Bels","year":"2021","journal-title":"Eur. Urol. Focus"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.urology.2017.09.027","article-title":"Predictive Factors of De Novo Overactive Bladder After Artificial Urinary Sphincter Implantation in Men with Postprostatectomy Incontinence","volume":"113","author":"Ko","year":"2018","journal-title":"Urology"},{"key":"ref_43","first-page":"22","article-title":"Efficacy and safety of onabotulinumtoxin A injection in male patients with detrusor overactivity after stress urinary incontinence surgery","volume":"46","author":"Rubio","year":"2021","journal-title":"Actas Urol. Esp. (Engl. Ed)."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/3\/221\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:56:11Z","timestamp":1760122571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/3\/221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["toxins15030221"],"URL":"https:\/\/doi.org\/10.3390\/toxins15030221","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]}}}